Aardvark Therapeutics (NASDAQ:AARD) Upgraded by Raymond James Financial to Strong-Buy Rating

by · The Cerbat Gem

Aardvark Therapeutics (NASDAQ:AARD – Get Free Report) was upgraded by Raymond James Financial to a “strong-buy” rating in a research note issued to investors on Tuesday, MarketBeat.com reports.

Other analysts also recently issued research reports about the stock. Bank of America decreased their price objective on shares of Aardvark Therapeutics from $26.00 to $25.00 and set a “buy” rating for the company in a research note on Thursday, August 28th. Jones Trading initiated coverage on Aardvark Therapeutics in a report on Wednesday, October 1st. They issued a “buy” rating and a $33.00 price target on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Aardvark Therapeutics in a report on Monday. HC Wainwright reiterated a “buy” rating and set a $40.00 target price on shares of Aardvark Therapeutics in a research report on Tuesday, September 23rd. Finally, Royal Bank Of Canada decreased their price objective on shares of Aardvark Therapeutics from $19.00 to $18.00 and set an “outperform” rating for the company in a report on Friday, November 14th. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $32.44.

Read Our Latest Report on AARD

Aardvark Therapeutics Stock Performance

NASDAQ:AARD opened at $11.93 on Tuesday. The stock’s fifty day moving average is $11.96 and its 200 day moving average is $11.55. The firm has a market capitalization of $259.72 million and a PE ratio of -5.63. Aardvark Therapeutics has a fifty-two week low of $4.88 and a fifty-two week high of $19.58.

Aardvark Therapeutics (NASDAQ:AARD – Get Free Report) last announced its earnings results on Thursday, November 13th. The company reported ($0.75) earnings per share for the quarter, beating the consensus estimate of ($0.82) by $0.07.

Insider Transactions at Aardvark Therapeutics

In other Aardvark Therapeutics news, CEO Tien-Li Lee acquired 10,000 shares of the company’s stock in a transaction dated Monday, September 15th. The shares were purchased at an average cost of $9.66 per share, for a total transaction of $96,600.00. Following the completion of the purchase, the chief executive officer owned 1,543,384 shares in the company, valued at approximately $14,909,089.44. This trade represents a 0.65% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CFO Nelson Sun acquired 6,000 shares of Aardvark Therapeutics stock in a transaction that occurred on Tuesday, September 9th. The stock was acquired at an average cost of $8.07 per share, with a total value of $48,420.00. Following the purchase, the chief financial officer directly owned 105,484 shares of the company’s stock, valued at $851,255.88. This represents a 6.03% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders have acquired a total of 36,000 shares of company stock worth $305,630 in the last three months.

Institutional Trading of Aardvark Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of AARD. Citadel Advisors LLC raised its position in shares of Aardvark Therapeutics by 5.9% in the 3rd quarter. Citadel Advisors LLC now owns 1,359,883 shares of the company’s stock worth $18,073,000 after acquiring an additional 76,151 shares in the last quarter. Laurion Capital Management LP raised its holdings in Aardvark Therapeutics by 6.1% in the third quarter. Laurion Capital Management LP now owns 1,049,721 shares of the company’s stock worth $13,951,000 after purchasing an additional 60,653 shares in the last quarter. Cormorant Asset Management LP purchased a new stake in shares of Aardvark Therapeutics during the first quarter valued at about $6,009,000. Vanguard Group Inc. boosted its holdings in shares of Aardvark Therapeutics by 20.6% in the 3rd quarter. Vanguard Group Inc. now owns 555,721 shares of the company’s stock valued at $7,386,000 after buying an additional 94,744 shares in the last quarter. Finally, Braidwell LP purchased a new position in shares of Aardvark Therapeutics in the 1st quarter worth approximately $3,755,000.

About Aardvark Therapeutics

(Get Free Report)

Aardvark Therapeutics, Inc operates as a biotechnology company. It engages in the development of a novel small molecule therapeutics for obesity and metabolic diseases. The company was founded by Tien Lee in 2017 and is headquartered in San Diego, CA.

Featured Articles